Inside the Industry with Kim Laipple

About Inside the Industry with Kim Laipple

Inside the Industry with Kim Laipple is where the leaders shaping the future of life sciences share the stories behind the science. Hosted by Kimberly Laipple, President of Scientific Search, each episode features candid conversations with CEOs, founders, scientists, investors, and commercial leaders about the pivotal decisions, breakthroughs, hiring strategies, and leadership lessons driving innovation. Whether you're building a company, advancing a career, or passionate about innovation, Inside the Industry delivers meaningful conversations with the people moving life sciences forward.

Publisher

Kim Laipple

Category

business · science

Language

en

Explicit

No

First episode

30 Jul 2026

Latest episode

26 Oct 2026

Latest episodes

7 episodes in the feed.

1. 

   26 Oct 2026

   Inside the Industry with Kim Laipple| Ep7 Rani Powers Founder and CEO Pluto Bio

   Keywords life sciences, biological data, AI in science, drug discovery, computational biology, data analysis, scientific decision-making, Pluto Bio, molecular biology, uncertainty in science AI, science, productivity, architect mindset, compounding knowledge, bioinformatics, drug discovery, clinical trials, innovation, life sciences Summary In this conversation, Dr. Rani Powers, founder and CEO of Pluto Bio, discusses the challenges and opportunities in modern scientific research, particularly in the context of data analysis and the integration of AI. The discussion covers the evolution of scientific decision-making, the need for better tools in data analysis, the transition from scientist to CEO, the bottlenecks in data utilization, and the complexities of omics research. Dr. Powers emphasizes the importance of understanding the implications of data and the necessity of bridging the gap between preclinical and clinical trials to enhance drug discovery. In this conversation, Kim Laipple and Rani discuss the transformative role of AI in science, emphasizing the importance of asking the right questions and the potential risks of outsourcing critical thinking to AI. They explore the architect mindset necessary for maximizing productivity and the compounding of knowledge in scientific research. The discussion also touches on the democratization of bioinformatics and the future of drug discovery, highlighting the need for adaptive clinical trials and the evolution of roles within the life sciences. Takeaways We have more biological data, computational power, and AI than ever before. The software available to scientists often hinders rather than helps their research. Rethinking data analysis can lead to more effective scientific outcomes. Transitioning from a scientist to a CEO involves embracing uncertainty. Understanding data implications is crucial for making informed decisions. AI can process unstructured data, but trust in its insights is essential. The complexity of biology requires a networked approach to research. Preclinical models are never perfect, but understanding their limitations is key. Investing in the right experiments can yield higher scientific confidence. The ultimate goal is to get effective drugs to patients efficiently. AI enhances our ability to ask important questions. Caution is needed when outsourcing thinking to AI. The future of work will require us to adapt to AI. Productivity gains depend on how we use AI. An architect mindset is crucial for true productivity. AI can help prevent duplicated work in research. Designing environments for AI use is essential. Clinical trials are evolving towards real-time data. The democratization of bioinformatics can free up specialists. The future of drug discovery will be radically different.

2. 

   19 Oct 2026

   Inside the Industry with Kim Laipple: Ep6 | Yann Jouvenot N6 The PCR Revolution

   Summary In this conversation, Kim Laipple and Jan Jouvenot discuss the evolution of PCR technology and its implications for molecular biology. They explore the limitations of traditional PCR methods and introduce the concept of adaptive amplification, which allows for real-time control of individual PCR reactions. The discussion highlights the importance of understanding the biological truth in samples and the transformative potential of new technologies in genomic workflows. In this conversation, Yann Jouvenot and Kim Laipple discuss the critical role of automation in life sciences, emphasizing the need for efficient workflows to reduce human costs. They explore the challenges of adopting new technologies in scientific protocols, highlighting the importance of empathy in overcoming resistance to change. The discussion also touches on the future of genomics labs, the significance of data quality and integrity, and the impact of AI on scientific research. Takeaways PCR has been a foundation of molecular biology for decades. Jan Jouvenot emphasizes the importance of adapting technology to meet real-world needs. Over amplification in PCR can lead to artifacts that compromise data quality. Adaptive amplification allows for tailored PCR cycles based on sample needs. The traditional approach to PCR does not account for the variability in sample quality. Innovative solutions can eliminate unnecessary steps in genomic workflows. Understanding market needs is crucial for successful product development. The evolution of genomics has made once-impossible techniques a reality. Single-cell sequencing benefits significantly from adaptive amplification. The future of PCR technology lies in its ability to provide real-time control and adaptability. Automation should be reserved for critical tasks. Inefficient workflows have a significant human cost. Scientists often resist change due to superstition. Empathy is key in technology adoption. Validation from peers is more effective than marketing. Data quality will be paramount in the future. The quest for truth in published data is essential. AI's ability to generate papers raises concerns Accountability in data generation is crucial. The future of genomics will focus on pushing limits

3. 

   21 Sept 2026

   Inside the Industry with Kim Laipple: Ep5 with James Piacentino CEO Thrive Genetics

   📙 Connect With Us: ▪️Follow Kimberly Laipple on LinkedIn: https://www.linkedin.com/in/kimberlylaipple/ (https://www.linkedin.com/in/kimberlylaipple/) ▪️Scientific Search on LinkedIn: https://www.linkedin.com/company/scientific-search/ (https://www.linkedin.com/company/scientific-search/) ▪️About Scientific Search: https://scientificsearch.com/ (https://scientificsearch.com/) ▪️Follow Scientific Search on Facebook: https://www.facebook.com/scientificsearch/ (https://www.facebook.com/scientificsearch/) ▪️Follow Scientific Search on X (Twitter): https://x.com/scientificsch (https://x.com/scientificsch) 📙Connect with James Piacentino https://www.linkedin.com/in/jamespiacentino/ (https://www.linkedin.com/in/jamespiacentino/) https://jamespiacentino.com/ (https://jamespiacentino.com/) https://thrivegenetics.ai/ (https://thrivegenetics.ai/) 📙 Keywords addiction, family, genetics, environment, habits, pain management, mental health, Thrive Genetics, addiction risk, behavioral science patient management, cost implications, oncology, workflow integration, addiction management, data-driven decisions, healthcare innovation, personal reflections, purpose, impact 📙 Summary In this conversation, James J. Piacentino discusses the complexities of addiction, particularly how it manifests within families and the interplay of genetics, environment, and behavior. He shares personal experiences with addiction in his family and emphasizes the importance of understanding addiction risk, especially in the context of pain management. Piacentino also highlights the innovative work of Thrive Genetics in addressing addiction through a scientific lens, aiming to provide better insights into individual addiction risks and behaviors. In this conversation, James J. Piacentino discusses the complexities of patient management, particularly in oncology, and the financial implications of treating patients as potential addicts. He explores innovative approaches to workflow integration in healthcare, emphasizing the importance of data in understanding addiction risks. Piacentino reflects on his personal journey and the purpose behind his work, highlighting the significance of suffering in shaping his mission to create impactful solutions in addiction management.

4. 

   7 Sept 2026

   Inside the Industry with Kim Laipple: Ep4 with Leo Pranitis Premier Dental

   In this conversation, Kim Laipple and Leo discuss the intricacies of innovation in the dental industry, exploring Leo's journey from advertising to becoming an executive in dental product development. They delve into the importance of clinician feedback, the challenges of introducing new products, and the role of experience in understanding user needs. Leo shares insights on becoming an inventor and the excitement of launching innovative products at Premier Dental, emphasizing the need for a deep understanding of clinician workflows to drive successful adoption of new technologies. In this conversation, Kim Laipple and Leo discuss the latest innovations in dentistry, focusing on antimicrobial solutions and the challenges of brand perception in the dental market. They explore lessons learned from product launch failures, the transition from large organizations to startups, and the importance of curiosity and humility in career transitions. The discussion also touches on the future of dentistry, emphasizing the need for global access to dental care and the role of smart materials in improving patient outcomes.TakeawaysInnovation in dentistry is often misunderstood and underutilized. Clinician feedback is crucial for successful product development. Experience in the field can significantly enhance product innovation. Understanding user needs is more important than personal opinions. The journey from idea to adoption involves many complexities. Effective questioning can uncover valuable insights from clinicians. Resistance to change is common among clinicians; understanding their perspective is key. Product development must consider multiple aspects, including workflow and pricing. Collaboration with technical teams is essential for successful innovation. Creating a culture of innovation attracts talent and drives growth. Antimicrobial solutions are crucial for dental restorations. Market research is essential for product validation. Brand perception can hinder innovation in established companies. Learning from product failures is vital for future success. Transitioning to a smaller organization requires unlearning previous habits. Curiosity and humility are key traits for career growth. Global access to dental care is a pressing issue. Smart materials are the future of dental products. Innovation in dentistry is often unseen by the public. Understanding market needs is critical for product adoption. Key Points Keywords dentistry, innovation, product development, clinician feedback, dental technology, dental products, user experience, dental industry, dental health care, dental innovation dentistry, antimicrobial solutions, product launch, brand perception, career transition, dental innovation, market challenges, dental materials, global access, smart materials

5. 

   31 Aug 2026

   Inside the Industry with Kim Laipple Ep 3 | Anton Xavier CEO

   Episode 3: Building Biotech in a Tough Market | Funding, Cancer Resistance & Entrepreneurship with Anton Xavier What does it really take to build and lead biotech companies in a challenging funding environment? In this episode of Inside the Industry, host Kim Laipple sits down with Anton Xavier, scientist, biotech entrepreneur, venture mentor, and CEO of iNanoRNA Therapeutics and K9 Biotech, for an in-depth conversation about the realities of building early-stage biotech companies. A major focus of the discussion is cancer resistance and tumor heterogeneity. Anton explains why targeting cancer through a single mechanism can lead to treatment resistance and describes the scientific rationale behind a multimodal microRNA approach designed to target multiple mechanisms of cancer biology through a single therapeutic strategy. Looking ahead, Anton shares his five-year vision for both organizations, including clinical development, Phase II opportunities, licensing deals, M&A, and potential public-market milestones. In this episode: ▪️ Building and leading early-stage biotech companies ▪️ Biotech funding and venture capital ▪️ The changing biotech investment environment ▪️ Lessons from Pfizer and big pharma ▪️ Go/no-go decisions in drug development ▪️ Translational science and commercialization ▪️ Cancer resistance and tumor heterogeneity ▪️ Multimodal microRNA therapeutics ▪️ Oncology and infectious disease ▪️ Animal health and human health innovation ▪️ African swine fever and unmet medical needs ▪️ Proof-of-concept studies in animal health ▪️ SBIR and non-dilutive funding ▪️ Clinical PIs and biotech development ▪️ Licensing, M&A and the future of biotech 📙 Connect With Us: ▪️Follow Kimberly Laipple on LinkedIn: https://www.linkedin.com/in/kimberlylaipple/ (https://www.linkedin.com/in/kimberlylaipple/) ▪️Scientific Search on LinkedIn: https://www.linkedin.com/company/scientific-search/ (https://www.linkedin.com/company/scientific-search/) ▪️About Scientific Search: https://scientificsearch.com/ (https://scientificsearch.com/) ▪️Follow Scientific Search on Facebook: https://www.facebook.com/scientificsearch/ (https://www.facebook.com/scientificsearch/) ▪️Follow Scientific Search on X (Twitter): https://x.com/scientificsch (https://x.com/scientificsch) 📙 Connect With Anton: ▪️Follow Anton Xavier on LinkedIn: linkedin.com/in/anton-xavier-3809b71b (http://linkedin.com/in/anton-xavier-3809b71b) ▪️iNanoRNA Therapeutics on LinkedIn: https://www.linkedin.com/company/inanorna-therapeutics/ (https://www.linkedin.com/company/inanorna-therapeutics/) ▪️K9 Biotech on LinkedIn: https://www.linkedin.com/company/k9-biotech/ (https://www.linkedin.com/company/k9-biotech/) 📙 𝐃𝐈𝐒𝐂𝐋𝐀𝐈𝐌𝐄𝐑: The views expressed by guests are their own and are shared for educational and informational purposes only. 📙 𝐂𝐎𝐏𝐘𝐑𝐈𝐆𝐇𝐓 𝐍𝐎𝐓𝐈𝐂𝐄: © Inside the Industry with Kim Laipple. All rights reserved. Unauthorized use, reproduction, or distribution of this content is prohibited.

6. 

   17 Aug 2026

   Episode 2: Jason Amsbaugh Samba Scientific | Why Great Science Doesn’t Sell Itself

   Episode 2: Why Great Science Doesn’t Sell Itself | Biotech Marketing, AI & Scientific Communication Why doesn’t great science always sell itself? In Episode 2 of Inside the Industry, Kim Laipple sits down with Jason, Founder & CEO of Sumba Scientific, to explore the intersection of science, business, marketing, commercialization, and AI in the life sciences industry. Jason shares his journey from working as a biochemist and cancer drug discovery researcher to building a marketing agency focused specifically on biotech and life science companies. Together, Kim and Jason examine why having strong scientific technology isn't enough to guarantee commercial success—and why understanding your customers, their problems, and the value of your solution is essential. 📙 In This Episode: ✔ Why great science doesn't automatically sell itself ✔ Jason's journey from bench science to biotech marketing ✔ Transitioning from scientific research to sales and strategy ✔ How biotech companies can identify ideal customers ✔ Customer discovery and product-market fit ✔ Marketing problems vs. product and sales problems ✔ How scientific data builds credibility and trust ✔ Why brand awareness alone doesn't generate revenue ✔ Sales vs. marketing in early-stage biotech companies ✔ How customer applications shape marketing messaging ✔ The impact of AI on biotech and life science marketing ✔ AI-generated content vs. human creativity ✔ Why AI answers should be "trust but verify" ✔ Transparency and scientific data validation ✔ Misinformation and trust in science ✔ The future of life science marketing and commercialization Whether you're a scientist, biotech founder, life science entrepreneur, marketer, sales professional, or innovation leader, this conversation offers practical insights into turning complex scientific innovation into clear value, stronger customer relationships, and commercial success.

7. 

   30 Jul 2026

   Inside the Industry with Kim Laipple: Ep 1 Trio Pharma|Patrick Doyle

   Episode 1: Patrick Doyle, CEO of Trio Pharmaceuticals Episode Description What does it really take to bring breakthrough therapies from the lab to patients? In the premiere episode of Inside the Industry, Kim Laipple sits down with Patrick Doyle, CEO of Trio Pharmaceuticals, to discuss the realities of biotech leadership, drug development, fundraising, and innovation. With more than 25 years of experience spanning startups and global pharmaceutical leaders including Novo Nordisk and Roche, Patrick shares the pivotal moments that shaped his career, lessons learned through both success and failure, and why the best biotech leaders let data—not emotion—guide critical decisions. The conversation explores the challenges of raising capital in today's market, the importance of experienced leadership teams, Trio's innovative Trailbody™ platform for targeted cancer therapies, and emerging technologies such as artificial intelligence and synthetic organ development that could reshape the future of medicine. Whether you're a biotech executive, scientist, investor, entrepreneur, or simply passionate about healthcare innovation, this episode offers valuable insights into the people and decisions driving the life sciences industry forward. In This Episode Patrick's journey from scientist to biotech CEO Leadership lessons from Novo Nordisk and Roche Navigating setbacks in drug development What investors look for in biotech companies How Trio's Trailbody™ platform targets cancer cells Why "kill early" is a critical biotech philosophy AI's role in drug discovery and development The future of regenerative medicine and synthetic organs Building resilient teams and making data-driven decisions About Patrick Doyle Patrick Doyle is the CEO of Trio Pharmaceuticals. Throughout his career, he has helped build and lead multiple biotechnology companies, raised more than $300 million across seven ventures, and contributed to four successful acquisitions. Prior to Trio, he served in executive leadership roles at K Bio, Stellexis Bioscience, Novo Nordisk, and Roche. Connect Trio Pharmaceuticals: https://www.triopharmaceuticals.com (https://www.triopharmaceuticals.com) Patrick Doyle: https://www.linkedin.com/in/pj-doyle/ (https://www.linkedin.com/in/pj-doyle/) Scientific Search: https://www.scientificsearch.com (https://www.scientificsearch.com) If you enjoyed this episode, be sure to subscribe, leave a review, and share it with colleagues in biotech, pharmaceuticals, and healthcare innovation. #InsideTheIndustry #Biotech #LifeSciences #Pharmaceuticals #DrugDevelopment #Biotechnology #Leadership #CancerResearch #HealthcareInnovation #ScientificSearch

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

1 ratings

Contact Inside the Industry with Kim Laipple

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.